Close

ShiraTronics Inc receives FDA Breakthrough Device Designation for Chronic Migraine Neurostimulation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EHR Health IT Solutions Among Others Impacting Patient Fate

EHR Health IT solutions and also telehealth platforms, patient...

EHRA asks HHS to Modernizing the Regulatory Approach to RFI

The HIMSS Electronic Health Record Association in the US...

AI in Patient Engagement Clocking Around 22% CAGR by 2029

AI in patient engagement – market size in 2029 Let...

Medical Device Manufacturers to Boost in Saudi Arabia

The Ministry of Industry and Mineral Resources of Saudi...

ShiraTronics, Inc. a privately held medical device company, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the FDA for its innovative neurostimulation therapy targeting the millions of chronic migraine sufferers.

The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

“We are thrilled to have received this important designation from the FDA. This reinforces the severity of the disability these patients suffer and the importance of new therapy options,” said Lynn Elliott, Chief Executive Officer of ShiraTronics, Inc.

“We applaud FDA’s Breakthrough Device designation on behalf of the millions of patients suffering from chronic migraine who are actively seeking treatment options to deal with this life limiting and severely disabling condition,” said Mudit K. Jain, PhD, a co-founder and Chairman of the Board of ShiraTronics, Inc.

Latest stories

Related stories

EHR Health IT Solutions Among Others Impacting Patient Fate

EHR Health IT solutions and also telehealth platforms, patient...

EHRA asks HHS to Modernizing the Regulatory Approach to RFI

The HIMSS Electronic Health Record Association in the US...

AI in Patient Engagement Clocking Around 22% CAGR by 2029

AI in patient engagement – market size in 2029 Let...

Medical Device Manufacturers to Boost in Saudi Arabia

The Ministry of Industry and Mineral Resources of Saudi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back